Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase EARLY_PHASE1 1Phase 3 1Phase 2/3 1Phase 1/2 1Phase 1 1

Status

Recruiting 2Terminated 1Completed 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 4

Conditions

Sarcoma 39Lymphoma 38Lymphoma, Large B-Cell, Diffuse 28Lymphoma, Non-Hodgkin 22Osteosarcoma 15Burkitt Lymphoma 14Hodgkin Disease 13Testicular Neoplasms 11Recurrence 9Leukemia 9Neuroectodermal Tumors, Primitive, Peripheral 8Lymphoma, Large-Cell, Immunoblastic 8Lymphoma, Follicular 8Lymphoma, B-Cell, Marginal Zone 8Teratoma 7Ovarian Neoplasms 7Lymphoma, Mantle-Cell 7Leukemia, Lymphocytic, Chronic, B-Cell 7Testicular Germ Cell Tumor 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Neuroblastoma 6Carcinoma, Embryonal 6Breast Neoplasms 6Rhabdomyosarcoma 5Lymphoma, Large-Cell, Anaplastic 5Endodermal Sinus Tumor 5Central Nervous System Neoplasms 5Urinary Bladder Neoplasms 4Neoplasms, Germ Cell and Embryonal 4Lymphoma, B-Cell 4

Interventions

Rituximab 45Cyclophosphamide 34Doxorubicin 16fludarabine 14Prednisone 14Vincristine 13Etoposide 13ibrutinib 10Mycophenolic Acid 8Bortezomib 8Magnetic Resonance Spectroscopy 7Lenalidomide 7Cytarabine 7pembrolizumab 6Immunotherapy, Adoptive 6polatuzumab vedotin 5fludarabine phosphate 5Whole-Body Irradiation 5Vorinostat 5Tacrolimus 5Specimen Handling 5CT-P10 5obinutuzumab 4ibritumomab tiuxetan 4Nivolumab 4Ifosfamide 4Carmustine 4Carboplatin 4Antilymphocyte Serum 4tafasitamab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Lymphoma, B-Cell × Ifosfamide × Clear all
NCT05821088 2025-11-20

Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma

Ohio State University Comprehensive Cancer Center

Phase 2 Recruiting
37 enrolled
Lymphoid

Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT07081022 2025-08-21

JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma

Shanghai Junshi Bioscience Co., Ltd.

Phase 2 Recruiting
180 enrolled
Lymphoid

Lymphoma, B-Cell

NCT02592876 2019-05-17

Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma

Seagen Inc.

Phase 2 Terminated
81 enrolled 15 charts
Lymphoid

Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Neoplasms, Neoplasms by Histologic Type, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT00588094 2015-12-04

Dose Augmented Rituximab and ICE for Pts With Primary Refractory and Poor Risk Relapsed Aggressive B-Cell NHL

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
20 enrolled 6 charts
Lymphoid

Lymphoma, Neoplasms, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡